甘李药业：甘精胰岛素注射液及其预填充注射笔获得埃塞俄比亚药品注册批件

Core Viewpoint - The company has received regulatory approval from the Ethiopian National Food and Drug Administration for its insulin products, indicating a significant step in expanding its market presence in Ethiopia [1] Group 1: Product Approval - The company announced the approval of its Glargine Insulin Injection and Glargine Insulin Injection Pre-filled Pen registration certificates [1] - The product is named BasalinTM, indicated for diabetes treatment, and is available in two forms: 3ml at 100 units/ml in vial and 3ml at 100 units/ml in pre-filled pen [1] - Glargine insulin is a long-acting insulin that requires subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours [1]